SG11201911704UA - Antisense oligonucleotides for modulating the function of a t cell - Google Patents
Antisense oligonucleotides for modulating the function of a t cellInfo
- Publication number
- SG11201911704UA SG11201911704UA SG11201911704UA SG11201911704UA SG11201911704UA SG 11201911704U A SG11201911704U A SG 11201911704UA SG 11201911704U A SG11201911704U A SG 11201911704UA SG 11201911704U A SG11201911704U A SG 11201911704UA SG 11201911704U A SG11201911704U A SG 11201911704UA
- Authority
- SG
- Singapore
- Prior art keywords
- modulating
- cell
- function
- antisense oligonucleotides
- antisense
- Prior art date
Links
- 108020000948 Antisense Oligonucleotides Proteins 0.000 title 1
- 239000000074 antisense oligonucleotide Substances 0.000 title 1
- 238000012230 antisense oligonucleotides Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Developmental Biology & Embryology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG10201705285SA SG10201705285SA (en) | 2017-06-27 | 2017-06-27 | Antisense oligonucleotides |
PCT/SG2018/050313 WO2019004939A1 (en) | 2017-06-27 | 2018-06-27 | Antisense oligonucleotides for modulating the function of a t cell |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201911704UA true SG11201911704UA (en) | 2020-01-30 |
Family
ID=64742433
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201705285SA SG10201705285SA (en) | 2017-06-27 | 2017-06-27 | Antisense oligonucleotides |
SG11201911704UA SG11201911704UA (en) | 2017-06-27 | 2018-06-27 | Antisense oligonucleotides for modulating the function of a t cell |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201705285SA SG10201705285SA (en) | 2017-06-27 | 2017-06-27 | Antisense oligonucleotides |
Country Status (9)
Country | Link |
---|---|
US (1) | US20200377883A1 (en) |
EP (1) | EP3645724A4 (en) |
JP (1) | JP7284718B2 (en) |
KR (1) | KR20200035937A (en) |
CN (1) | CN111630167A (en) |
AU (1) | AU2018291556B2 (en) |
CA (1) | CA3066035A1 (en) |
SG (2) | SG10201705285SA (en) |
WO (1) | WO2019004939A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109477073B (en) * | 2016-03-31 | 2024-04-12 | 来恩生物医药私人有限公司 | Non-activated T cells expressing exogenous virus specific T Cell Receptors (TCRs) |
US11312963B2 (en) * | 2018-10-18 | 2022-04-26 | Synerk Inc. | Compositions and methods for inhibiting TIGIT gene expression |
CA3132178A1 (en) | 2019-04-02 | 2020-10-08 | Aliye Seda Yilmaz-Elis | Antisense oligonucleotides for immunotherapy |
CN109988842B (en) * | 2019-04-19 | 2022-12-06 | 上海吉玛制药技术有限公司 | Reagent group for in-situ detection of PDL1 by oligonucleotide labeled probe and application thereof |
WO2020219977A1 (en) * | 2019-04-26 | 2020-10-29 | Stoke Therapeutics, Inc. | Methods and compositions for modulating splicing of alternative introns |
CN110157705B (en) * | 2019-05-16 | 2021-06-18 | 苏州安天圣施医药科技有限公司 | Antisense oligonucleotide for inhibiting PD-1 signal at PDCD1 gene expression splicing level and screening method and application thereof |
JP7337373B2 (en) * | 2019-07-29 | 2023-09-04 | サイアス株式会社 | Method for producing antigen-specific T cells |
US20230036569A1 (en) * | 2019-12-17 | 2023-02-02 | The General Hospital Corporation | Engineered immune cells with reduced toxicity and uses thereof |
WO2021173812A1 (en) * | 2020-02-28 | 2021-09-02 | Aligos Therapeutics, Inc. | Methods and compositions for targeting pd-l1 |
US20230183708A1 (en) * | 2020-04-30 | 2023-06-15 | Secarna Pharmaceuticals Gmbh & Co. Kg | PD-1-specific antisense oligonucleotide and its use in therapy |
EP4211241A1 (en) * | 2020-09-10 | 2023-07-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of splice switching oligonucleotides for exon skipping-mediated knockdown of nf-kb components in b cells |
WO2022084389A1 (en) * | 2020-10-20 | 2022-04-28 | Immunoa Pte. Ltd. | Modified immune cells |
WO2022136140A1 (en) | 2020-12-22 | 2022-06-30 | F. Hoffmann-La Roche Ag | Oligonucleotides targeting xbp1 |
WO2023073709A1 (en) * | 2021-10-27 | 2023-05-04 | Hadasit Medical Research Services & Development Ltd. | Nucleic acid agents modulating pd-1 isoforms |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6566132B1 (en) * | 2001-04-26 | 2003-05-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of Interferon gamma receptor 1 expression |
US8501704B2 (en) * | 2005-11-08 | 2013-08-06 | Sarepta Therapeutics, Inc. | Immunosuppression compound and treatment method |
CA2628093A1 (en) * | 2005-11-08 | 2007-05-18 | Avi Biopharma, Inc. | Antisense oligonucleotide analog compounds targeting proprocessed ctla-4 mrna |
HUE035799T2 (en) * | 2006-05-10 | 2018-05-28 | Sarepta Therapeutics Inc | Oligonucleotide analogs having cationic intersubunit linkages |
EP2295543A1 (en) * | 2009-09-11 | 2011-03-16 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for the preparation of an influenza virus |
WO2011120101A1 (en) * | 2010-04-01 | 2011-10-06 | The University Of Queensland | Small rna molecules and methods of use |
EP2825665B1 (en) * | 2012-03-14 | 2017-09-06 | Ruprecht-Karls-Universität Heidelberg | Epigenetic signatures as marker for cardiomyopathies and myocardial insufficiencies |
US20150017136A1 (en) * | 2013-07-15 | 2015-01-15 | Cellectis | Methods for engineering allogeneic and highly active t cell for immunotherapy |
WO2014078749A1 (en) * | 2012-11-15 | 2014-05-22 | The Regents Of The University Of California | Splice modulating oligonucleotides that inhibit cancer |
WO2014090985A1 (en) * | 2012-12-13 | 2014-06-19 | Universität Leipzig | T-cell modulation by exon skipping |
CN103820454B (en) * | 2014-03-04 | 2016-03-30 | 上海金卫生物技术有限公司 | The method of CRISPR-Cas9 specific knockdown people PD1 gene and the sgRNA for selectively targeted PD1 gene |
AU2015247323B2 (en) * | 2014-04-18 | 2021-07-01 | Editas Medicine, Inc. | CRISPR-Cas-related methods, compositions and components for cancer immunotherapy |
US9828601B2 (en) * | 2015-02-27 | 2017-11-28 | Idera Pharmaceuticals, Inc. | Compositions for inhibiting checkpoint gene expression and uses thereof |
IL254734B2 (en) * | 2015-03-27 | 2023-09-01 | Harvard College | Modified t cells and methods of making and using the same |
JP6949728B2 (en) * | 2015-05-29 | 2021-10-13 | ジュノー セラピューティクス インコーポレイテッド | Compositions and Methods for Modulating Inhibitory Interactions in Genetically Engineered Cells |
KR20180133840A (en) * | 2015-12-04 | 2018-12-17 | 노파르티스 아게 | Compositions and methods for immuno-oncology |
-
2017
- 2017-06-27 SG SG10201705285SA patent/SG10201705285SA/en unknown
-
2018
- 2018-06-27 WO PCT/SG2018/050313 patent/WO2019004939A1/en active Search and Examination
- 2018-06-27 EP EP18823314.2A patent/EP3645724A4/en active Pending
- 2018-06-27 SG SG11201911704UA patent/SG11201911704UA/en unknown
- 2018-06-27 CA CA3066035A patent/CA3066035A1/en not_active Abandoned
- 2018-06-27 CN CN201880043866.7A patent/CN111630167A/en active Pending
- 2018-06-27 KR KR1020207000349A patent/KR20200035937A/en unknown
- 2018-06-27 AU AU2018291556A patent/AU2018291556B2/en not_active Expired - Fee Related
- 2018-06-27 US US16/626,395 patent/US20200377883A1/en active Pending
- 2018-06-27 JP JP2019572710A patent/JP7284718B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA3066035A1 (en) | 2019-01-03 |
KR20200035937A (en) | 2020-04-06 |
WO2019004939A1 (en) | 2019-01-03 |
EP3645724A1 (en) | 2020-05-06 |
JP2020530981A (en) | 2020-11-05 |
CN111630167A (en) | 2020-09-04 |
SG10201705285SA (en) | 2019-01-30 |
AU2018291556A1 (en) | 2020-01-02 |
EP3645724A4 (en) | 2021-07-21 |
JP7284718B2 (en) | 2023-05-31 |
US20200377883A1 (en) | 2020-12-03 |
AU2018291556B2 (en) | 2021-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201911704UA (en) | Antisense oligonucleotides for modulating the function of a t cell | |
AU201713759S (en) | Multi-hole cartridge | |
AU201713736S (en) | Cartridge | |
SG11202101913PA (en) | INHIBITING aV ß6 INTEGRIN | |
IL273915A (en) | Cell | |
ZA201808291B (en) | Antisense oligonucleotides for modulating htra1 expression | |
ZA202007542B (en) | Oligonucleotides for modulating scn9a expression | |
GB201713078D0 (en) | T Cell Modification | |
GB201707783D0 (en) | Cell | |
GB201707779D0 (en) | Cell | |
IL279056A (en) | Oligonucleotides for modulating tau expression | |
PL3372324T3 (en) | Long cartridge case | |
GB201720949D0 (en) | Cell | |
IL279929A (en) | Oligonucleotides for modulating rtel1 expression | |
EP3449002A4 (en) | G-quadruplex-containing antisense oligonucleotides | |
IL276357A (en) | Oligonucleotides for modulating tmem106b expression | |
IL271039A (en) | Antisense oligonucleotides for modulating htra1 expression | |
EP3532617A4 (en) | Antisense oligonucleotides | |
GB201718697D0 (en) | Cell | |
IL272732A (en) | Activity modulator | |
EP3565825A4 (en) | Snap25 antisense oligonucleotides | |
GB201714330D0 (en) | Oligonucleotides | |
GB201714718D0 (en) | Cell | |
GB201814450D0 (en) | Antisense oligonucleotides | |
SG11201912447RA (en) | Tyrosinase antisense oligonucleotides |